Toshio Kitawaki

Dr. Toshio Kitawaki

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ATAtsushi Tanaka
Atsushi Tanaka
HNHiroyoshi Nishikawa
Hiroyoshi Nishikawa
SNShinsuke Noguchi
Shinsuke Noguchi
DSDaisuke Sugiyama
Daisuke Sugiyama
Hiromasa MorikawaHiromasa Morikawa
Hiromasa Morikawa
SSShimon Sakaguchi
Shimon Sakaguchi
This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK expressed in T cells. We showed that imatinib-treated CML patients in complete molecular remission (CMR) exhibited selective depletion of effector T reg (eT reg) cells and significant increase in effector/memory CD8+ T cells while non-CMR patients did not. Imatinib at CML-therapeutic concentrations indeed induced apoptosis specifically in eT reg cells and expanded tumor antigen–specific CD8+ T cells in vitro in healthy individuals and melanoma patients, and suppressed colon tumor growth in vivo in mice. Mechanistically, because of FoxP3-dependent much lower expression of LCK and ZAP-70 in T reg cells compared with other T cells, imatinib inhibition of LCK further reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptotis. Taken together, eT reg cell depletion by imatinib is instrumental in evoking effective immune responses to various cancers.

27 August 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
HYHepei Yuan
Hepei Yuan
MNMomoko Nishikori
Momoko Nishikori
YOYasuyuki Otsuka
Yasuyuki Otsuka
HAHiroshi Arima
Hiroshi Arima
TKToshio Kitawaki
Toshio Kitawaki
ATAkifumi Takaori‐Kondo
Akifumi Takaori‐Kondo
An inhibitor of the histone methyltransferase enhancer of zeste homologue 2 (EZH2), tazemetostat, has been developed for the treatment of B‐cell lymphoma, but its mechanisms of action are not fully elucidated. We screened for genes targeted by tazemetostat in eleven B‐cell lymphoma cell lines and found that tazemetostat significantly increased the expression of chemokine (C‐C motif) ligand 17 (CCL17)/thymus‐ and activation‐regulated chemokine (TARC) in all, which codes for a chemokine that is a hallmark of Hodgkin/Reed‐Sternberg (H/RS) cells in Hodgkin lymphoma. Notably, gene set enrichment analysis demonstrated a positive correlation between the genes upregulated by tazemetostat in five follicular lymphoma (FL) cell lines and those reported to be overexpressed in H/RS cells. The CCL17 promoter region was enriched in repressive histone modification H3K27me3, and tazemetostat induced H3K27 demethylation and activated gene transcription. CCL17 protein secretion was also induced by EZH2 inhibition, which was further enhanced by concurrent CpG stimulation. In vitro transwell migration assay demonstrated that CCL17 produced by tazemetostat‐treated B cells enhanced the recruitment of T cells, which had the potential to exert antilymphoma response. Analysis of publicly available human lymphoma databases showed that CCL17 gene expression was inversely correlated with the EZH2 activation signature and significantly paralleled the CD4+ and CD8+ T‐cell–rich signature in FL and germinal center B‐cell–like diffuse large B‐cell lymphoma. Our findings indicate that tazemetostat can potentially activate antilymphoma response by upregulating CCL17 expression in B‐cell lymphoma cells and promote T‐cell recruitment, which provides a rationale for its combination with immunotherapy.

26 January 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NNNaokazu Nakamura
Naokazu Nakamura
TJTomoyasu Jo
Tomoyasu Jo
YAYasuyuki Arai
Yasuyuki Arai
TKToshio Kitawaki
Toshio Kitawaki
MNMomoko Nishikori
Momoko Nishikori
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
Prolonged hematotoxicity is the most common long-term adverse event in chimeric antigen receptor (CAR) T-cell therapy. In order to evaluate the impact on prolonged cytopenia of inflammatory status after CAR-T cell infusion, we performed a single-center retrospective study and analyzed patients with B-cell lymphomas after CAR-T cell infusion. Among 90 patients analyzed 90 days after infusion, cumulative incidence was 57.5% for prolonged neutropenia, 36.7% for anemia, and 49.8% for thrombocytopenia. Patients who experienced cytokine-release syndrome (CRS) had significantly higher incidence and longer duration of prolonged cytopenia. In addition, we found that among patients with grade 1 CRS, those who had longer duration of CRS-related symptoms (>5days; grade 1b in modified CRS grading [m-CRS]) had significantly higher incidence and longer duration of prolonged cytopenia than those whose CRS-related symptoms resolved within 5 days (grade 1a in m-CRS). Multivariate analysis revealed that a higher m-CRS grade (grade 1b or 2; hazard ratio [HR], 2.42), higher peak CRP (≥10mg/dL; HR, 1.66), longer duration of elevated CRP (≥10days; HR, 1.83), and a decrease in serum inorganic phosphorus concentration (≥30% from baseline; HR, 1.95) were associated with significantly higher cumulative incidence of prolonged neutropenia, as well as anemia and thrombocytopenia. Using these factors, we developed a new predictive scoring model for prolonged hematotoxicity, the "KyoTox a-score", which successfully stratified incidence and duration of cytopenia independently from the existing model, CAR-HEMATOTOX, which is based on laboratory data at lymphodepletion. Thus, this newly developed post-CAR-T inflammation-dependent score is accurate and useful to predict prolonged hematotoxicity.

16 October 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
KIKen‐Ichi Ishiyama
Ken‐Ichi Ishiyama
TKToshio Kitawaki
Toshio Kitawaki
YOYasuyuki Otsuka
Yasuyuki Otsuka
ATAkifumi Takaori‐Kondo
Akifumi Takaori‐Kondo
NKNorimitsu Kadowaki
Norimitsu Kadowaki
TOToshiyuki Ohtsuka
Toshiyuki Ohtsuka
Dasatinib treatment markedly increases the number of large granular lymphocytes including natural killer (NK) cells in a proportion of Ph+ leukemia patients, which associates with a better prognosis. In‐depth immune profiling of NK cells can predict therapeutic response in these patients. In the present study, we showed that CD56‐negative (CD56neg) NK cells increased exclusively in cytomegalovirus‐seropositive (CMV+) patients treated with dasatinib. The increase longitudinally paralleled with progressive differentiation of CD56dim NK cells during dasatinib therapy driven by CMV reactivation as shown by principal component analysis on 19 NK cell markers. The CD56neg NK cells showed downregulation of NK‐activating receptors, upregulation of PD‐1, and lower cytotoxicity and cytokine production, indicating that these cells are anergic and dysfunctional as seen in chronic infections with HIV‐1 or hepatitis C virus. Moreover, cytolytic activity of CD56dim and CD56neg NK cells against leukemia cells was partially restored by nivolumab in proportion to the frequency of PD‐1+ NK cells. The proportion of patients who achieved deep molecular responses at 2 years was significantly higher in dasatinib‐treated patients with ≥3% CD56neg NK cells than in those with fewer CD56neg NK cells (54.5% vs 15.8%, P = .0419). These findings suggest that CD56neg NK cells may be an exhausted population induced by chronic activation through CMV reactivation during dasatinib therapy. Expansion of CD56neg NK cells is a hallmark of chronic NK cell activation in patients treated with dasatinib and may predict a better clinical outcome. Furthermore, PD‐1 blockade may enhance anti‐leukemia responses of such NK cells.

Verified
Journal Article
Open access
PDF file
JBJuan Camilo Baena
Juan Camilo Baena
LLLucy Perez Lugo
Lucy Perez Lugo
Alejandro Toro-PedrozaAlejandro Toro-Pedroza
Alejandro Toro-Pedroza
TKToshio Kitawaki
Toshio Kitawaki
ALAlexandre Roumenov Loukanov
Alexandre Roumenov Loukanov
Cancer treatment has traditionally focused on eliminating tumor cells but faces challenges such as resistance and toxicity. A promising direction involves targeting the tumor microenvironment using CAR T cell immunotherapy, which has shown potential for treating relapsed and refractory cancers but is limited by high costs, resistance, and toxicity, especially in solid tumors. The integration of nanotechnology into ICAM cell therapy, a concept we have named “CAR T nanosymbiosis”, offers new opportunities to overcome these challenges. Nanomaterials can enhance CAR T cell delivery, manufacturing, activity modulation, and targeting of the tumor microenvironment, providing better control and precision. This approach aims to improve the efficacy of CAR T cells against solid tumors, reduce associated toxicities, and ultimately enhance patient outcomes. Several studies have shown promising results, and developing this therapy further is essential for increasing its accessibility and effectiveness. Our “addition by subtraction model” synthesizes these multifaceted elements into a unified strategy to advance cancer treatment paradigms.

4 November 2024 in eJHaem
Verified
Journal Article
Open access
RHRyota Hamada
Ryota Hamada
YAYasuyuki Arai
Yasuyuki Arai
TKToshio Kitawaki
Toshio Kitawaki
NNNaokazu Nakamura
Naokazu Nakamura
MMMasanobu Murao
Masanobu Murao
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
Introduction: Patients undergoing chimeric antigen receptor (CAR) T‐cell therapy face prolonged treatment timelines and are prone to cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) after infusion. Disabilities in physical function and the importance of rehabilitation during CAR‐T‐cell therapy to maintain physical function have been poorly documented.Method: We performed a retrospective cohort study to assess changes in exercise tolerance via differences in a 6‐min‐walking distance (Δ6MWD) and factors influencing it.Results: A total of 77 patients who underwent rehabilitation during CAR‐T‐cell therapy were enrolled, and their 6MWD was 450 m (median, range 180–705 m) before and 450.5 m (107.0–735.0 m) 30 days after CAR‐T treatment. No significant alteration in Δ6MWD was observed overall (11.0 m, 95% confidence interval, −56.1 to 88.2 m). Multiple regression analyses indicated that age (over vs. under 65 years) revealed no notable differences in Δ6MWD (20 vs. 10 m), while ΔHb (β = 0.24, p = 0.03), moderate/severe CRS (grade 1 with continuous fever or grade ≥2; β = −0.25, p = 0.03), and ICANS (any grade; β = −0.22, p = 0.04) were significantly associated with lower Δ6MWD.Conclusion: This real‐world study indicated that CAR‐T‐cell therapy is less likely to reduce physical function even in older patients if rehabilitation is properly performed, whereas CRS and ICANS can be risk factors to deprive exercise tolerance.